About this episode
We emerged from the COVID -19 pandemic in 2022 to headlines about unseasonably early spikes in respiratory syncytial virus and concerns and threats of a triple pandemic of CV19, influenza, and RSV. Fortunately, there’s been no triple pandemic, but what has emerged is multiple first-time vaccine approvals for RSV. Dr. John Schoen, Senior Manager of Drug Information at The Vizient Center for Phamacy Practice Excellence joins his colleague and Program Host Stacy Lauderdale, Associate Vice President of Evidence-Based Medicine to discuss the use of the RSV vaccines.
Guest speakers:
John Schoen, PharmD, BCPS
Senior Manager of Drug Information
Vizient Center for Pharmacy Practice Excellence
Host:
Stacy Lauderdale, PharmD, BCPS
Associate Vice President of Evidence-Based Medicine
Vizient Center for Pharmacy Practice Excellence
Show Notes:
[00:55-01:46] John’s background
[01:47 -03:15] The RSV disease burden in older adults, and risk factors
[03:16-04:42] The relative disease severity of RSV versus influenza
[04:43-07:04] Vaccine uptake during the last RSV season
[07:05-8:35] Efficacy of the RSV vaccines in observational data compared to the clinical trials
[8:36-11:22] Changes in ACIP recommendations
[11:23-13:14] Potential benefits of RSV vaccination for ages older than 75
[13:15-15:32] Potential adverse reactions of RSV vaccines
[15:33-18:31] Comparisons of the RSV vaccines
[18:32-20:46] Are patients going to need more than one RSV vaccine?
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed
